Clinical trials located in

Uherské Hradiště

Uherské Hradiště city is located in Czechia. Currently, 3 clinical trials are being conducted in this city.

Uherské Hradiště, nestled in the Moravian part of the Czech Republic, was founded in 1257 by King Ottokar II of Bohemia. This city is a tapestry of historical and cultural richness, boasting a well-preserved historical center with Renaissance and Baroque buildings. It is the heart of the Moravian Slovakia region, known for its vibrant folklore traditions, including the annual Slovácký rok folk festival. The city is also a gateway to the wine-producing region of Slovácko, making it a pivotal center for traditional Moravian wine culture. The nearby White Carpathians add a natural charm to the city’s picturesque setting.

  • CT-EU-00117178

    Comparing a Denosumab to Prolia® in postmenopausal women with osteoporosis

    This here clinical trial is a Phase 3 study aimin’ to compare a new biosimilar drug called Enzene Denosumab (ENZ215) with the already approved drug Prolia®. The study is lookin’ for postmenopausal women with osteoporosis, which is a condition where the bones become weak and brittle.

    The main goal is to see if this new drug ENZ215 works just as well as Prolia® in increasin’ the bone mineral density in the lower back over a period of 360 days. They’ll be measurin’ this by takin’ special X-ray scans called DXA scans.

    Another important thing they’ll be checkin’ is how the two drugs affect the levels of a certain protein in the blood called C-telopeptide of Type-1 collagen (sCTX). This protein is a marker of bone breakdown, so they’ll be lookin’ at how much it changes over the first 180 days of the study.

    Overall, this study aims to see if this new biosimilar drug ENZ215 is just as good as Prolia® in treatin’ osteoporosis in postmenopausal women, both in terms of increasin’ bone density and reducin’ bone breakdown.

    • Denosumab
  • Study of the new oral drug LY3871801 for rheumatoid arthritis

    The aim of this study is to test a new drug called LY3871801 for people suffering from moderate to severe rheumatoid arthritis. The main goal is to see if this new drug can help reduce disease activity and improve symptoms better than a placebo. In the first part of the study, doctors will check how much the Disease Activity Score changes after 12 weeks of taking LY3871801 or a placebo. Then, in the second part, they will look at what percentage of patients experience significant improvement, defined as achieving an ACR50 response, which means reducing symptoms of rheumatoid arthritis by 50% or more. Both the real drug and the placebo will be taken by mouth.

    • placebo
    • LY3871801
  • Evaluating SAR441566 in Adults with Moderate-to-Severe Rheumatoid Arthritis

    This clinical trial is designed to explore the effectiveness and safety of a new medication called SAR441566 in adults who are dealing with moderate-to-severe rheumatoid arthritis (RA). If you’re an adult who hasn’t found relief from RA with methotrexate alone and haven’t tried biologic or targeted synthetic disease-modifying anti-rheumatic drugs yet, this study might be of interest to you.

    The study is set up as a double-blind, placebo-controlled experiment, which means neither you nor the study team will know if you’re receiving the actual medication or a placebo. This is a key part of ensuring the results are unbiased. You’ll be randomly placed into one of five groups, with some receiving SAR441566 and others a placebo, all alongside your regular methotrexate treatment.

    The trial will last for about 149 days, including a 6-week period before the treatment starts to confirm your eligibility, a 12-week treatment phase, and a 2-week follow-up period after treatment ends to monitor your safety. Throughout the study, you’ll visit the study center 8 times.

    One of the main goals of this study is to see if participants show a significant improvement in their RA symptoms, specifically looking for a 20% improvement in the American College of Rheumatology (ACR) score by week 12. This score measures various aspects of RA, including joint tenderness and swelling, pain levels, and overall physical function.

    By participating, you’ll be contributing to research that could lead to new treatment options for RA, potentially offering relief to many who are searching for more effective therapies.

    • SAR441566
    • placebo

See more clinical trials in other cities in Czechia:

.